Life Scientist > Lab Technology

Events down under

01 June, 2004 by Melissa Trudinger

A full roster of conferences in Australia and its Asia-Pacific neighbours make the region a good place to visit this year. To start with, Australia's BIO equivalent, AusBiotech2004, will this year be held in Brisbane from November 7-10, with a theme of 'Going Global'.


Aussies you'll meet at BIO

01 June, 2004 by Melissa Trudinger

Australia is home to a thriving and dynamic biotechnology industry with a firm footing in the world-class research base found in the universities and research institutions 'Down Under'.


BIO profile: Brian Whan, Molecular Plant Breeding CRC

01 June, 2004 by Graeme O'Neill

When the Victorian Department of Agriculture's Werribee research farm advertised for a 'Semi-Dwarf Wheat Breeder' in the early 1970s, Bryan Whan applied -- his qualifications measured up, even if his height exceeded specification.


Venture capital: adventurous times in biotech

01 June, 2004 by Renate Krelle

Positive forces are at work in Australian venture capital circles, writes Renate Krelle.


Trials without error: Australia's clinical capabilities

01 June, 2004 by Renate Krelle

The secret's out -- Australia is a great place to do clinical trials and contract research, as Renate Krelle discovers.


BIO profile: Harry Karelis, Biotech Capital

01 June, 2004 by Renate Krelle

UK and European biotechs may not have heard of Australian historian Geoffrey Blainey. But Harry Karelis, of Sydney venture capitalist Biotech Capital, says both British and continental biotechs are just as conscious as Australians are of Blainey's most famous concept -- the tyranny of distance.


BIO profile: Andy Gearing, BioComm

01 June, 2004 by Melissa Trudinger

Dr Andy Gearing believes wholeheartedly that big pharma and big biotech overseas should take a closer look at what the Australian biotechnology and life sciences sector has to offer.


BIO profile: John Mattick, Institute for Molecular Bioscience

01 June, 2004 by Melissa Trudinger

Australia's research institutes and industry have a mutual responsibility, says Prof John Mattick -- to work together to translate academic ideas into ideas for development and commercialisation.


BIO profile: Mervyn Jacobson, Genetic Technologies

01 June, 2004 by Melissa Trudinger

A keen fascination in the creative ideas of others and a willingness to take risks are hallmarks of Australian biotechnology entrepreneur Dr Mervyn Jacobson's outlook on life.


BIO profile: Jurgen Michaelis, Bio Innovation SA

01 June, 2004 by Graeme O'Neill

Start-ups are the easy bit -- it's the quality and consistency of post-natal care that determines whether young biotechnology companies will survive, according to Dr Jurgen Michaelis, the man behind the rapid rise of South Australia's biotechnology industry.


BIO profile: Alison Coutts, eG Capital

01 June, 2004 by Iain Scott

One of the most serendipitous moments in the recent history of Australian biobusiness occurred when Alison Coutts met Mark Fordree, Iain Scott learns.


From in vitro to in vivo: Australian biotech grows up

01 June, 2004 by Melissa Trudinger

Since last year's BIO, the Australian biotechnology sector has been all about growth, writes Melissa Trudinger.


I’s dotted and t’s crossed on BresaGen restructure

26 May, 2004 by Renate Krelle

The administrators of Adelaide biotech BresaGen (ASX:BGN) today formalised the agreement the company has made with Queensland-based public unlisted biotech company CBio by executing a Deed of Company Arrangement for the restructure of the company.


EU patent snatchback won't affect GTG: Jacobson

21 May, 2004 by Graeme O'Neill

The European Patent Office's decision to revoke a key patent on a breast cancer test owned by Utah-based Myriad Genetics will not prevent Myriad's Australian licensee, Genetic Technologies Ltd (ASX: GTG) providing the test in Australia and Asia.


Victorians get $60 million for innovation infrastructure

21 May, 2004 by Melissa Trudinger

The Victorian State Government will fund another round of the Science Technology Innovation Infrastructure Grants program (STII), providing $60 million to supports biomedical, environmental, agricultural, manufacturing and ICT infrastructure projects.


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd